3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Burkitt Lymphoma
19
Lymphoma, Large B-Cell, Diffuse
15
Multiple Myeloma
14
Lymphoma, Non-Hodgkin
12
Lymphoma, Follicular
11
Lymphoma
11
Leukemia, Myeloid, Acute
11
Recurrence
10
Ovarian Neoplasms
8
Myelodysplastic Syndromes
8
Lymphoma, B-Cell
8
Pancreatic Neoplasms
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Leukemia
7
Lymphoma, Mantle-Cell
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Hodgkin Disease
6
Hematologic Neoplasms
6
Breast Neoplasms
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
5
Leukemia, Myelomonocytic, Chronic
5
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Sarcoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Osteosarcoma
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, B-Cell, Marginal Zone
4
Interventions
fludarabine
1
Cyclophosphamide
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymic epithelial tumor
×
Cyclophosphamide
×
30 days
×
Clear all
NCT07598955
2026-05-20
SELECT-NK-THYM
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled